Local recurrence after surgery for early stage lung cancer
Top Cited Papers
Open Access
- 3 November 2009
- Vol. 115 (22) , 5218-5227
- https://doi.org/10.1002/cncr.24625
Abstract
BACKGROUND: The objective of the current study was to evaluate the actuarial risk of local failure (LF) after surgery for stage I to II nonsmall cell lung cancer (NSCLC) and assess surgical and pathologic factors affecting this risk.METHODS: The records, including pertinent radiologic studies, of all patients who underwent surgery for T1 to T2, N0 to N1 NSCLC at Duke University between 1995 and 2005 were reviewed. Risks of disease recurrence were estimated using the Kaplan‐Meier method. A multivariate Cox regression analysis assessed factors associated with LF in the entire cohort and a subgroup undergoing optimal surgery for stage IB to II disease.RESULTS: For all 975 consecutive patients, the 5‐year actuarial risk of local and/or distant disease recurrence was 36%. First sites of failure were local only (25%), local and distant (29%), and distant only (46%). The 5‐year actuarial risk of LF was 23%. On multivariate analysis, squamous/large cell histology (hazards ratio [HR], 1.98), stage > IA (HR, 2.02), and sublobar resections (HR, 1.99) were found to be independently associated with a higher risk of LF. For the subset of patients (n = 445) undergoing at least a lobectomy with negative surgical margins and currently considered for adjuvant chemotherapy (stage IB‐II disease), the 5‐year actuarial risk of LF was 27%. Within this subgroup, squamous/large cell histology (HR, 2.5) and lymphovascular space invasion (HR, 1.74) were associated with a higher risk of LF. The 5‐year rate of LF was 13%, 32%, and 47%, respectively, with 0, 1, or 2 risk factors.CONCLUSIONS: Greater than half of disease recurrences after surgery for early stage NSCLC involved local sites. Pathologic factors may help to distinguish those patients at highest risk. Cancer 2009. © 2009 American Cancer Society.Keywords
This publication has 32 references indexed in Scilit:
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative GroupJournal of Clinical Oncology, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- A Genomic Strategy to Refine Prognosis in Early-Stage Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small Cell Lung CancerThe Annals of Thoracic Surgery, 2005
- CONSORT statement: extension to cluster randomised trialsBMJ, 2004
- Post-operative adjuvant thoracic radiotherapy for patients with completely resected non-small cell lung cancer with nodal involvement: outcome and prognostic factorsThe British Journal of Radiology, 2004
- Effectiveness of Postoperative Irradiation in Stage IIIA Non–Small Cell Lung Cancer According to Regression Tree Analyses of Recurrence RisksThe Annals of Thoracic Surgery, 1997
- Postresection Irradiation for T2 N0 M0 Non–Small Cell Carcinoma: A Prospective, Randomized StudyThe Annals of Thoracic Surgery, 1996
- Incidence of local recurrence and second primary tumors in resected stage I lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 1995
- Site of Recurrence in Patients with Stages I and II Carcinoma of the Lung Resected for CureThe Annals of Thoracic Surgery, 1981